OXYMATRINE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H24N2O2
Molecular Weight	264.3633
Optical Activity	UNSPECIFIED
Defined Stereocenters	5 / 5
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[O-][N@+]12CCC[C@H]3CN4[C@H](CCCC4=O)[C@@H](CCC1)[C@@H]23

InChI

InChIKey=XVPBINOPNYFXID-JARXUMMXSA-N

InChI=1S/C15H24N2O2/c18-14-7-1-6-13-12-5-3-9-17(19)8-2-4-11(15(12)17)10-16(13)14/h11-13,15H,1-10H2/t11-,12+,13+,15-,17+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C15H24N2O2
Molecular Weight	264.3633
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	4 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26009496 | https://www.ncbi.nlm.nih.gov/pubmed/25672672

Oxymatrine is one of the key components extracted from Sophora flavescens, a leguminous plant grown in China, Japan, and some European countries. It has attracted much attention because of its low toxicity and side effects. Extensive research over the past decades have revealed various important pharmacological activities of oxymatrine under in vitro and in vivo conditions, including anti-inflammation, immunoregulatory, antihepatitis virus infection, antihepatic fibrosis, antianaphylaxis, and other immune regulation. Oxymatrine has been extensively studied for their cancer chemopreventive potential against various cancers, for instance, human pancreatic cancer, gastric cancer, breast cancer, lung cancer, osteosarcoma, and leukemia. However, the precise mechanisms underlying the anticancer activity of oxymatrine are largely unknown.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Solute carrier family 22 member 1 18 Target ID: O15245 Gene ID: 6580.0 Gene Symbol: SLC22A1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24291757	Inhibitor 8504		513.0 µM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic hepatitis B 16 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27236147	Secondary		Phase IV 63	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
392.33 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18647475/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
20519 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
247 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
364.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2057 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
1431.53 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18647475/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
20436 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
3841 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
1205 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
30470 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18647475/	300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
2.17 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.43 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16500065/	600 mg single, intravenous dose: 600 mg route of administration: Intravenous experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
2.87 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	OXYMATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23747322/	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	MATRINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.6 g 1 times / day multiple, intravenous Studied dose Dose: 0.6 g, 1 times / day Route: intravenous Route: multiple Dose: 0.6 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/28112799/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/28112799/	Sources: https://pubmed.ncbi.nlm.nih.gov/28112799/
300 mg 3 times / day multiple, oral Studied dose Dose: 300 mg, 3 times / day Route: oral Route: multiple Dose: 300 mg, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15484298/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/15484298/	Sources: https://pubmed.ncbi.nlm.nih.gov/15484298/

PubMed

Title	Date	PubMed
Arsenic trioxide-induced hERG K(+) channel deficiency can be rescued by matrine and oxymatrine through up-regulating transcription factor Sp1 expression.	2013-01-01	23103450
Oxymatrine prevents NF-κB nuclear translocation and ameliorates acute intestinal inflammation.	2013	23568217
Effect of Oxymatrine on the TGFbeta-Smad signaling pathway in rats with CCl4-induced hepatic fibrosis.	2008-04-07	18395914
Effects of oxymatrine on experimental hepatic fibrosis and its mechanism in vivo.	2005-01-14	15633229
Immunomodulatory effect of oxymatrine on induced CCl4-hepatic fibrosis in rats.	2004-12	15603720
[IFN or oxymatrine in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B].	2004-03	15340535

Patents

Sample Use Guides

In Vivo Use Guide

Therapeutic doses of the substantially pure oxymatrine are administered twice daily at a dose of between about 5 mg and about 500 mg per administration

Route of Administration: Oral

In Vitro Use Guide

Human hepatome call lines Hep-G2 and SMMC-7721 were incubated with oxymatrine at concentrations 0.25 to 2.5 mg/ml for 24 to 48 hours, and was found that the growth and proliferation of hepatoma cells decreased in a time-dependent manner.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:29:03 GMT 2025` Edited by `admin` on `Mon Mar 31 19:29:03 GMT 2025`
Record UNII	85U4C366QS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(4R,7AS,13AR,13BR,13CS)-DODECAHYDRO-1H,5H,10H-DIPYRIDO(2,1-F:3',2',1'-IJ)(1,6)NAPHTHYRIDIN-10-ONE 4-OXIDE

Preferred Name

English

OXYMATRINE

Common Name

English

(7AS,13AR,13BR,13CS)-DODECAHYDRO-1H,5H,10H-DIPYRIDO(2,1-F:3',2',1'-IJ)(1,6)NAPHTHYRIDIN-10-ONE 4-OXIDE

Common Name

English

Oxymatrine [WHO-DD]

Common Name

English

Code System Code Type Description

SMS_ID

100000127812